Trial reporteLife2018
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
Trial report in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02451072 (The Role of 5-HT2A Receptor on Perception of the Self and Perception of Meaning in Healthy Volunteers), which is not on this map. Cited by 207 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Role of 5-HT2A Receptor on Perception of the Self and Perception of Meaning in Healthy Volunteers
Who cites it
207 citing papers in PubMed, 7 syntheses or guidelines pooled it, 399 citations in OpenAlex.
- Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.Molecular psychiatry · 2025Pooled it
- What fMRI studies say about the nature of the psychedelic effect: a scoping review.Frontiers in neuroscience · 2025Pooled it
- Drug-drug interactions involving classic psychedelics: A systematic review.Journal of psychopharmacology (Oxford, England) · 2024Pooled it
- The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.CNS drugs · 2023Pooled it
- Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.Neuroscience and biobehavioral reviews · 2023Pooled it
- Dose-response relationships of LSD-induced subjective experiences in humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Pooled it
- Default Mode Network Modulation by Psychedelics: A Systematic Review.The international journal of neuropsychopharmacology · 2023Pooled it
- Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026Trial
- Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.Molecular psychiatry · 2025Trial
- Neural mechanisms of psychedelic visual imagery.Molecular psychiatry · 2025Trial
- Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Brain connectivity changes to fast versus slow dopamine increases.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Ketamine induces multiple individually distinct whole-brain functional connectivity signatures.eLife · 2024Trial
- Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats.Translational psychiatry · 2023Trial
- Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Trial
- Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.Psychopharmacology · 2022Trial
- Repeated low doses of LSD in healthy adults: A placebo-controlled, dose-response study.Addiction biology · 2022Trial
- Trial
- MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Background: Lysergic acid diethylamide (LSD) has agonist activity at various serotonin (5-HT) and dopamine receptors. Despite the therapeutic and scientific interest in LSD, specific receptor contributions to its neurobiological effects remain unknown. Methods: We therefore conducted a double-blind, randomized, counterbalanced, cross-over studyduring which 24 healthy human participants received either (i) placebo+placebo, (ii) placebo+LSD (100 µg po), or (iii) Ketanserin, a selective 5-HT2A receptor antagonist,+LSD. We quantified resting-state functional connectivity via a data-driven global brain connectivity method and compared it to cortical gene expression maps. Results: LSD reduced associative, but concurrently increased sensory-somatomotor brain-wide and thalamic connectivity. Ketanserin fully blocked the subjective and neural LSD effects. Whole-brain spatial patterns of LSD effects matched 5-HT2A receptor cortical gene expression in humans. Conclusions: Together, these results strongly implicate the 5-HT2A receptor in LSD’s neuropharmacology. This study therefore pinpoints the critical role of 5-HT2A in LSD’s mechanism, which informs its neurobiology and guides rational development of psychedelic-based therapeutics. Funding: Funded by the Swiss National Science Foundation, the Swiss Neuromatrix Foundation, the Usona Institute, the NIH, the NIAA, the NARSAD Independent Investigator Grant, the Yale CTSA grant, and the Slovenian Research Agency. Clinical trial number: NCT02451072
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.